BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37298373)

  • 1. Targeting IGF2BP3 in Cancer.
    Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
    Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
    Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
    Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
    Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of the N
    Deng L; Di Y; Chen C; Xia J; Lei B; Li N; Zhang Q
    Cell Death Dis; 2024 Mar; 15(3):181. PubMed ID: 38429265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
    Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
    Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
    Fan J; Zhuang M; Fan W; Hou M
    PeerJ; 2023; 11():e15706. PubMed ID: 37663284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma.
    Du M; Peng Y; Li Y; Sun W; Zhu H; Wu J; Zong D; Wu L; He X
    Cell Death Discov; 2022 Feb; 8(1):53. PubMed ID: 35136045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1.
    Yang Z; Zhao F; Gu X; Feng L; Xu M; Li T; Liu X; Zhang X
    Am J Cancer Res; 2021; 11(4):1428-1445. PubMed ID: 33948366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
    Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
    Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization.
    Qin J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H; Cai J
    Transl Oncol; 2023 Nov; 37():101764. PubMed ID: 37643553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of
    Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
    DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
    Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
    Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2BP3/HIF1A/YAP signaling plays a role in driving acute-on-chronic liver failure through activating hepatocyte reprogramming.
    Cheng K; Liu S; Li C; Zhao Y; Wang Q
    Cell Signal; 2023 Aug; 108():110727. PubMed ID: 37257765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. circRNA N6-methyladenosine methylation in preeclampsia and the potential role of N6-methyladenosine-modified circPAPPA2 in trophoblast invasion.
    Zhang Y; Yang H; Long Y; Zhang Y; Chen R; Shi J; Chen J
    Sci Rep; 2021 Dec; 11(1):24357. PubMed ID: 34934095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of m6A RNA methylation in cancer.
    Sun T; Wu R; Ming L
    Biomed Pharmacother; 2019 Apr; 112():108613. PubMed ID: 30784918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.